Vanda Pharmaceuticals Inc. (VNDA) reported third-quarter 2026 revenue of $1.6 million, far below the $70.6 million estimate and down sharply year over year. The company also posted a wider operating loss and remained unprofitable for the quarter.
Key quarterly figures included:
Cash used in operating activities came to -$31.1 million, while cash and cash equivalents stood at $61.9 million. Total liabilities increased to $182.5 million, reflecting a larger balance-sheet burden as the period ended.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Vanda Pharmaceuticals Inc. Hedge Fund Activity
We have seen 85 institutional investors add shares of Vanda Pharmaceuticals Inc. stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 1,894,119 shares (+118.1%) to their portfolio in Q2 2026, for an estimated $11,592,008
- EMPIRE FINANCIAL MANAGEMENT COMPANY, LLC removed 922,245 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,644,139
- QUBE RESEARCH & TECHNOLOGIES LTD added 729,212 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,462,777
- AIGH CAPITAL MANAGEMENT LLC removed 705,831 shares (-25.7%) from their portfolio in Q2 2026, for an estimated $4,319,685
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 646,256 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,955,086
- MARSHALL WACE, LLP added 629,994 shares (+105.7%) to their portfolio in Q2 2026, for an estimated $3,855,563
- BLACKROCK, INC. added 377,749 shares (+5.2%) to their portfolio in Q2 2026, for an estimated $2,311,823
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
